---
title: 'Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells
  in systemic mastocytosis: a registry study of the European Competence Network on
  Mastocytosis'
date: '2025-01-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39815050/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250116170922&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Expression of CD2, CD25 and/or CD30 in extracutaneous mast cells (MC)
  is a minor diagnostic criterion for systemic mastocytosis (SM) in the classification
  of the World Health Organization and International Consensus Classification. So
  far, it remains unknown whether expression of these antigens on MC is of prognostic
  significance in SM. We performed a retrospective multi-center study of patients
  with SM using the data set of the registry of the European Competence Network on
  ...
disable_comments: true
---
Expression of CD2, CD25 and/or CD30 in extracutaneous mast cells (MC) is a minor diagnostic criterion for systemic mastocytosis (SM) in the classification of the World Health Organization and International Consensus Classification. So far, it remains unknown whether expression of these antigens on MC is of prognostic significance in SM. We performed a retrospective multi-center study of patients with SM using the data set of the registry of the European Competence Network on ...